GlaxoSmithKline Announce That They Plan To Publish Clinical Trial Data

The pharmaceutical giant, GlaxoSmithKline, last week announced that they plan to publish all clinical trial results in order to preserve the safety of medicines. Usually clinical trial data is withheld, if it is found that a drug delivers disappointing results. However, to withhold such information is a clear attempt at distorting evidence and it raises doubts about the current safety of medicines available on the market. It has recently been exposed that a Type 2 diabetes drug named ‘Avandia’, led to heart failure and heart attacks in patients. GlaxoSmithKline’s decision to publish the results has come just over a year after they paid $3billion to settle compensation claims in the US.

Partner at Express, Daniel Slade, commented on the news: “I hope that GlaxoSmithKline will also include the data and information made available to those conducting the trials, or provide a response to the wide criticisms of the way those trials were conducted. It would also assist victims in the UK if they disclosed the reasons for parting with millions of dollars, in compensating thousands of diabetics in the US.”

Daniel Slade currently has 19 Avandia cases on his books and has begun proceedings against GlaxoSmithKline in four of them.

If you or someone you know has been effected by Avandia please feel free to contact us for free legal advice on 0800 158 5274.